Table 1 Comparison of Demographic and Clinical Characteristics Between Training and Test Cohorts
Characteristics | Training Cohort (n = 210) | Test Cohort (n = 90) | P value |
|---|---|---|---|
Age at assessment (in years), median (IQR) | 38 (27–49) | 37.5 (26-51.25) | 0.14 |
Disease duration, years, median (IQR) | 1 (0–4) | 2 (1–6) | 0.065 |
Gender | 0.919 | ||
Male, n (%) | 118 (56.2) | 50 (55.6) | |
Female, n (%) | 92 (43.8) | 40 (44.4) | |
BMI, median (IQR) | 20.8 (18.8–22.6) | 20.4 (18-22.4) | 0.18 |
Age at diagnosis (in years), n (%) | 0.925 | ||
A1 (≤ 16) | 17 (8.1) | 8 (8.9%) | |
A2 (17–40) | 117 (55.7) | 48 (53.3) | |
A3 (> 40) | 76 (36.2) | 34 (37.8) | |
Disease location, n (%) | 0.144 | ||
L1 (terminal ileum) | 46 (21.9) | 23 (25.6) | |
L2 (colon) | 12 (5.7) | 11 (12.2) | |
L3 (ileocolon) | 129 (61.4) | 50 (55.6) | |
L3 + L4 (L3 + upper gastrointestinal tract) | 23 (11) | 6 (6.7) | |
Disease phenotype, n (%) | 0.475 | ||
B1 (inflammatory) | 94 (44.8) | 40 (44.4) | |
B2 (stricturing) | 93 (44.3) | 44 (48.9) | |
B3 (penetrating) | 23 (11) | 6 (6.7) | |
Medication, n (%) | < 0.05 | ||
No medication | 30 (14.3) | 8 (8.9) | |
5-ASA | 45 (21.4) | 21 (23.3) | |
Corticosteroids | 22 (10.5) | 9 (10.0) | |
Immunosuppressant | 75 (35.7) | 17 (18.9) | |
Biologics | 84 (40.0) | 58 (64.4) | |
Perianal disease, n (%) | 85 (40.5) | 29 (32.2) | 0.177 |
Endoscopic disease activity, n (%) | 156 (74.3) | 69 (76.7) | 0.663 |